Literature DB >> 23515570

Role of CCR5Δ32 mutation in protecting patients with Schistosoma mansoni infection against hepatitis C viral infection or progression.

Amal Abdul-rasheed El-Moamly1, Mohamed Aly El-Sweify, Rafiaa M Rashad, Esam M Abdalla, Mostafa M Ragheb, Mohamed M Awad.   

Abstract

Schistosomiasis has been incriminated in the significant increase in hepatitis C virus (HCV) infections, although the association has not been adequately explained. We hypothesized that the CCR5Δ32 mutation may be involved in the high prevalence of HCV with schistosomiasis. The aim was to explore the association between the CCR5Δ32 mutation in schistosomiasis patients and protection against HCV infection or progression. We compared 220 schistosomiasis patients (S group) and 190 patients with HCV and schistosomiasis (HCV/S group) for the presence of the CCR5Δ32 mutation. Clinical, biochemical, and radiological assessments were done. HCV infection was diagnosed with anti-HCV antibodies and a recombinant HCV antigen-based rapid immunochromatographic test, and confirmed by HCV reverse transcriptase PCR. HCV genotyping was done by reverse hybridization line probe assay. Schistosomiasis was diagnosed by FAST-ELISA and indirect hemagglutination for Schistosoma mansoni antibodies, and stool analysis for ova. Polymorphisms of the CCR5 receptor gene were assessed by PCR-based genotyping of the 32-bp deletion at the CCR5 locus in whole blood. Of HCV/S patients, 91.6 vs. 91.8 % of S patients had CCR5 WT/WT homozygosity (nonmutants). Heterozygous and homozygous CCR5Δ32 mutation patterns (CCR5Δ32/WT and CCR5Δ32/Δ32) were distributed similarly in the HCV/S and S groups (6.8 vs. 7.2 % and 0.53 vs. 0.90 %, respectively; p > 0.05, OR = 0.97). Genotype 4 was the predominant viral genotype (93 % of cases). No differences were observed in CCR5 gene patterns according to viral genotype, viral RNA count, or ALT level. However, CCR5Δ32 mutants (homozygous and heterozygous) had a lower rate of severe hepatic fibrosis vs. nonmutants (27 vs. 42 %, p = 0.101, OR = 0.51). Moreover, 53.4 % of CCR5Δ32/WT mutants showed spontaneous viral clearance vs. 26.2 % of nonmutants (p = 0.000, OR = 4.1). In conclusion, no association was detected between the CCR5Δ32 mutation and HCV disease susceptibility in schistosomiasis patients. However, patients with the CCR5Δ32 mutation and HCV infection were less prone to severe hepatic fibrosis and more likely to have spontaneous viral clearance than patients with the nonmutant genotype.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23515570     DOI: 10.1007/s00436-013-3380-9

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.383


  40 in total

1.  Inhibition of HIV infection by CXCR4 and CCR5 chemokine receptor antagonists.

Authors:  E De Clercq; D Schols
Journal:  Antivir Chem Chemother       Date:  2001

2.  Schistosoma mansoni soluble egg antigens enhance HCV replication in mammalian cells.

Authors:  Mahmoud Mohamed Bahgat; Mohamed Abd-Elhafez El-Far; Ahmed Atef Mesalam; Amany Abd-Elghany Ismaeil; Ahmed Atef Ibrahim; Hossam Eid Gewaid; Amany Sayed Maghraby; Mohamed Ahmed Ali; Dina Nadeem Abd-Elshafy
Journal:  J Infect Dev Ctries       Date:  2010-05-01       Impact factor: 0.968

3.  Current status of S. mansoni infection in El-Prince village, Alexandria Governorate.

Authors:  Amel A El-Sahn; Abdel-Ghanny M El-Masry; Amany I Shehata; Hanan F Ibrahim
Journal:  J Egypt Public Health Assoc       Date:  2002

4.  Impact of National Schistosomiasis Control Program in Kafr El-Sheikh governorate, Nile Delta, Egypt: an independent evaluation.

Authors:  R Barakat; A Farghaly; H El Morshedy; M Hassan; de W Miller
Journal:  J Egypt Public Health Assoc       Date:  1998

5.  Use of chemokine receptors by poxviruses.

Authors:  A S Lalani; J Masters; W Zeng; J Barrett; R Pannu; H Everett; C W Arendt; G McFadden
Journal:  Science       Date:  1999-12-03       Impact factor: 47.728

6.  Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice.

Authors:  N Sato; W A Kuziel; P C Melby; R L Reddick; V Kostecki; W Zhao; N Maeda; S K Ahuja; S S Ahuja
Journal:  J Immunol       Date:  1999-11-15       Impact factor: 5.422

7.  Surveillance of acute hepatitis C in Cairo, Egypt.

Authors:  Maha M El Gaafary; Claire Rekacewicz; Amira Gamal Abdel-Rahman; Mohamed Farouk Allam; Mostafa El Hosseiny; Mohamed Abdel Hamid; Françoise Colombani; Yehia Sultan; Saeed El-Aidy; Arnaud Fontanet; Mostafa Kamal Mohamed
Journal:  J Med Virol       Date:  2005-08       Impact factor: 2.327

8.  Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay.

Authors:  L Stuyver; R Rossau; A Wyseur; M Duhamel; B Vanderborght; H Van Heuverswyn; G Maertens
Journal:  J Gen Virol       Date:  1993-06       Impact factor: 3.891

9.  CCR5 deficiency decreases susceptibility to experimental cerebral malaria.

Authors:  Elodie Belnoue; Michéle Kayibanda; Jean-Christophe Deschemin; Mireille Viguier; Matthias Mack; William A Kuziel; Laurent Rénia
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

10.  In vivo-activated CD4 T cells upregulate CXC chemokine receptor 5 and reprogram their response to lymphoid chemokines.

Authors:  K M Ansel; L J McHeyzer-Williams; V N Ngo; M G McHeyzer-Williams; J G Cyster
Journal:  J Exp Med       Date:  1999-10-18       Impact factor: 14.307

View more
  3 in total

1.  A Study on the Association between CCRΔ32 Mutation and HCV Infection in Iranian Patients.

Authors:  Farahnaz Bineshian; Asieh Hosseini; Zohre Sharifi; Afsaneh Aghaie
Journal:  Avicenna J Med Biotechnol       Date:  2018 Oct-Dec

Review 2.  Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases.

Authors:  Joel Henrique Ellwanger; Bruna Kulmann-Leal; Valéria de Lima Kaminski; Andressa Gonçalves Rodrigues; Marcelo Alves de Souza Bragatte; José Artur Bogo Chies
Journal:  Virus Res       Date:  2020-05-30       Impact factor: 3.303

3.  Clinical significance of the CCR5delta32 allele in hepatitis C.

Authors:  Isabelle Morard; Sophie Clément; Alexandra Calmy; Alessandra Mangia; Andrea Cerny; Andrea De Gottardi; Meri Gorgievski; Markus Heim; Raffaele Malinverni; Darius Moradpour; Beat Müllhaupt; David Semela; Stéphanie Pascarella; Pierre-Yves Bochud; Franco Negro
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.